Business Wire

CO-BONA

18.3.2024 09:06:33 CET | Business Wire | Press release

Share
Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification

Today, Bona® announced that four of its products are now certified by the U.S. Environmental Protection Agency (EPA) Safer Choice program and have earned the Safer Choice label. The new certification applies to the Bona Pet System™ including Bona Pet System™ Hard-Surface Floor Deep Cleaner and Bona Pet System™ Wood Floor Deep Cleaner as well as Bona’s OxyPower floor cleaners -- Bona OxyPower Hard-Surface Floor Deep Cleaner and Bona OxyPower Wood Floor Deep Cleaner. Safer Choice is a voluntary EPA program that certifies cleaning and other products made with ingredients that are safer for people, pets, and the planet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318768884/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification (Graphic: Business Wire)

“As we continue our journey to innovate cleaning solutions that bring out the beauty in floors, our primary focus is to leverage the latest technologies and research when it comes to ingredients,” said Marie Shore, Director Product Management EMEA & APAC, Bona.“Recognition like this one from the EPA Safer Choice program is a key milestone in validating our work for a more sustainable future.”

The Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. Every ingredient in products that carry the Safer Choice label is reviewed by EPA scientists to make sure certified products only contain the safest possible ingredients for people and the planet. Safer Choice-certified products are made with ingredients that won't cause serious health problems, like cancer, and aren't harmful to fish or waterways. Safer Choice also restricts volatile organic compounds to minimize indoor air pollution and associated respiratory concerns. Products with the label also use more sustainable packaging that doesn't contain toxic chemicals, like heavy metals.

Powered by hydrogen peroxide, Bona OxyPower Wood Floor Deep Cleaner and Bona OxyPower Hard-Surface Floor Deep Cleaner are specifically designed to remove heavy dirt build-up, providing a deep clean for wood or hard-surface floors. The ready-to-use, oxygenated, waterbased formula releases thousands of micro-bubbles that loosen heavy dirt build-up, removes stuck-on messes, and lifts away stains via a bubbling action to provide a deep clean for floors.

Formulated specifically for cleaning pet messes, The Bona Pet System Hard Surface Floor Deep Cleaner and Bona Pet System Wood Floor Deep Cleaner offer a deep clean by penetrating through tough stuck-on stains, tracked in dirt, and accident messes with the cleaning power of Hydrogen Peroxide. The Odour Guard Technology™ eliminates and neutralizes urine and other organic odours upon contact.

For more information about Bona Pet System and OxyPower cleaners are visit www.bona.com. These GREENGUARD certified products are available in EMEA and APAC regions.

“These four cleaning products were developed to meet the high standards of consumers as well as certifying organizations like the EPA Safer Choice program,” continued Shore. “With 11 Safer Choice certified products in North America it made sense to seek this certification for our products in Europe. It all aligns to our long-standing mission to minimize our environmental impact by innovating safer systems and products to the highest sustainability standards.”

About the EPA Safer Choice Program

Safer Choice incentivizes safer, greener chemistry by allowing companies to differentiate their products in the marketplace with the Safer Choice label. With thousands of certified products, the Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. For more information about the Safer Choice program, visit: www.epa.gov/saferchoice.

About Bona®

Bona® is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 4.1bn SEK (EUR 366million) 2023. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318768884/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye